In a landmark decision, India’s intellectual property office on Monday allowed Hyderabad-based Natco Pharma Ltd to make and sell a copycat version of German drug maker bayer AG’s patented cancer treatment Nexavar. It’s the first time that an Indian company has been granted the so-called compulsory licence to market a generic version of a patented drug. The drug, patented by bayer in India in 2008, is used in the treatment of...

-The Economic Times The government has allowed a local drugmaker to make and sell a patented cancer drug at a fraction of the price charged by Germany's bayer AG, setting a precedent for more such efforts by Indian firms and heightening the global pharmaceutical industry's anxiety over the use of the controversial compulsory licensing provision.  The outgoing patent controller of India, PH Kurian, on Monday granted the country's first compulsory licence to...

-The Economic Times   The government has allowed a local drugmaker to make and sell a patented cancer drug at a fraction of the price charged by Germany's bayer AG, setting a precedent for more such efforts by Indian firms and heightening the global pharmaceutical industry's anxiety over the use of the controversial compulsory licensing provision.  The outgoing patent controller of India, PH Kurian, on Monday granted the country's first compulsory licence to...

Maharashtra sounds clarion call on hybrid crop liability Competition is tough in the seed market, which may explain why marketing gimmicks are often used to woo farmers. It’s tougher still for the farmers to get compensation when the claims fail and they are saddled with a bad or damaged crop. Sometimes the state government steps in to offer compensation or the farmers turn to the consumer court for relief. Typically, of...

Rs 3 lakh – that's the price a pharmaceutical company has paid to the family of a person who died in their clinical trial. Others weren't even this lucky. According to the Drug Controller General of India's (DCGI) records, 25 people died in clinical trials carried out by nine pharmaceutical companies in 2010. Families of five of these victims received "compensation for trial related death" — the amount ranging from Rs...